


Dr. Middleton’s research concentrates on the development of new cancer drugs and on the treatment of melanoma and upper gastrointestinal tract cancers. He has overseen the development of internationally leading melanoma and upper GI clinical research groups and establishment of portfolios of early phase radiotherapy and hemato-oncology trials in Oxford. He is involved in the evaluation of novel immunotherapeutics, including pre-clinical development, trial design, proof of mechanism and proof of concept.
He studied medicine at Cambridge and Oxford and trained in medical oncology at the Christie Hospital.